Fluticasone Propionate And Salmeterol Powder
Product Images NDC 0093-7516

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 0093-7516). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1 (Image 1)

1 (Image 1)
FDA Label Image

2 (Image 10)

2 (Image 10)
FDA Label Image

Figure D (Image 11)

Figure D (Image 11)
FDA Label Image

Figure E (Image 12)

Figure E (Image 12)
FDA Label Image

1 (Image 13)

1 (Image 13)
FDA Label Image

Figure G (Image 14)

Figure G (Image 14)
FDA Label Image

1 (Image 15)

1 (Image 15)
FDA Label Image

1 (Image 16)

1 (Image 16)
This appears to be a description of a medication, specifically Fluticasone Propionate and Salmeterol Inhalation Powder, used for oral inhalation. Each blister contains 100 micrograms of Fluticasone Propionate, USP and 725 micrograms of Salmeterol Xinafoate USP equivalent to 50 micrograms of Salmeterol base with lactose. The text provides instructions on how to use the medication and proper breathing techniques. The manufacturer of the medication is Teva. No information is given on side effects or medical conditions this medication is designed to treat.*
FDA Label Image

1 (Image 17)

1 (Image 17)
FDA Label Image

1 (Image 18)

1 (Image 18)
This is a medication label for Fluticasone Proplonate and Salmeterol Inhalation Powder, USP. It contains instructions on how to use the inhaler and the dosage. The medication is used for inhalation only and comes in a pack of 60 blisters. The label includes precautions and potential side effects.*
FDA Label Image

1 (Image 2)

1 (Image 2)
FDA Label Image

1 (Image 3)

1 (Image 3)
This appears to be a medication prescription for Fluticasone Propionate and Salmeterol inhalation powder. It indicates a dosage of 100 micrograms of Fluticasone Propionate and 50 micrograms of Salmeterol to be taken twice daily. The following section seems to be a chart showing the results of a study where Fluticasone Propionate and Salmeterol were compared to Placebo. Unfortunately, due to the quality of the text obtained by , certain characters are corrupted and the nature of the study or the parameters of the chart are not clear.*
FDA Label Image

1 (Image 4)

1 (Image 4)
FDA Label Image

1 (Image 5)

1 (Image 5)
FDA Label Image

1 (Image 6)

1 (Image 6)
This is a clinical study evaluating the effects of Fluticasone propionate and salmeterol inhalation powder compared to a Placebo on lung function measured by FEV. The study involved patients taking either Fluticasone propionate and salmeterol inhalation powder, Salmeterol, or Placebo twice daily for a period of time indicated by the graph. The results suggest that Fluticasone propionate and salmeterol inhalation powder may improve lung function compared to Placebo.*
FDA Label Image

1 (Image 7)

1 (Image 7)
FDA Label Image

1 (Image 8)

1 (Image 8)
FDA Label Image

1 (Image 9)

1 (Image 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.